Chronic kidney illness (CKD) is amongst the most prevalent and dire problems of diabetes mellitus in adults throughout the world. Diabetes considerably contributes to the burden of kidney illness, such that one third to at least one half of CKD in the United States and many different international locations is attributable to diabetic kidney illness (DKD). As DKD progresses to end-stage renal illness (ESRD), sufferers are at heightened danger for atypical glycemic problems, together with the improvement of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes.
Furthermore, even in the absence of diabetes, hypoglycemia is a frequent incidence in CKD sufferers which will contribute to their excessive burden of heart problems and demise. Extrapolation of knowledge from scientific trials in high-cardiovascular-risk populations and observational research in sufferers with non-dialysis-dependent (NDD) CKD and ESRD recommend that reasonable glycemic targets outlined by glycated hemoglobin ranges of 6% to eight% and glucose ranges of 100 to 150 mg/dL are related to higher survival in DKD sufferers.
However, given the imprecision of glycated hemoglobin ranges in kidney illness, additional analysis is required to find out the optimum glycemic metric and goal in diabetic NDD-CKD and ESRD sufferers. Given their exceedingly excessive cardiovascular morbidity and mortality, there’s a compelling want for additional investigation of the way to optimally handle dysglycemia in the NDD-CKD and ESRD populations.
Dendritic Integration Dysfunction in Neurodevelopmental Disorders
Neurodevelopmental issues (NDDs) that have an effect on cognition, social interplay, and studying, together with autism spectrum dysfunction (ASD) and mental incapacity (ID), have a powerful genetic element. Our present understanding of danger genes highlights two most important teams of dysfunction: these in genes that act as chromatin modifiers and these in genes that encode for proteins localized at or close to synapses. Understanding how dysfunction in these genes contributes to phenotypes noticed in ASD and ID stays a serious query in neuroscience.
In this overview, we spotlight rising proof suggesting that dysfunction in dendrites – areas of neurons that obtain synaptic enter – could also be key to understanding options of neuronal processing affected in these issues. Dendritic integration performs a basic function in sensory processing, cognition, and acutely aware notion, processes hypothesized to be impaired in NDDs. Many high-confidence ASD genes perform inside dendrites the place they management synaptic integration and dendritic excitability.
Further, growing proof demonstrates that a number of ASD/ID genes, together with chromatin modifiers and transcription components, regulate the expression or scaffolding of dendritic ion channels, receptors, and synaptic proteins. Therefore, we talk about how dysfunction of subsets of NDD-associated genes in dendrites results in defects in dendritic integration and excitability and could also be one core phenotype in ASD and ID.
In vitro dissolution concerns related to nano drug supply techniques
Nano drug supply techniques (NDDS) supply promising answer for the translation of future nanomedicines. As bioavailability and therapeutic outcomes may be improved by altering the drug launch from these NDDS, it turns into important to completely perceive their drug launch kinetics. Moreover, U.S. Food and Drug Administration requires essential analysis of potential security, efficacy, and public well being impacts of nanomaterials. Spiraling up market share of NDDS has additionally stimulated the pharmaceutical trade to develop their cost-effective generic variations after the expiry of patent and related exclusivity.
However, in contrast to the standard dosage types, the in vivo disposition of NDDS is very intricate and totally different from their in vitro habits. Significant challenges exist in the institution of in vitro-in vivo correlation (IVIVC) attributable to incomplete understanding of nanoparticles’ in vivo biofate and its influence on in vitro experimental protocols. A rational design of dissolution might function high quality and amount management instrument and assist develop a significant IVIVC for favorable financial implications. Clinically related drug product specs (essential high quality attributes) may be recognized by establishing a hyperlink between in vitro efficiency and in vivo publicity.
In vitro dissolution can also play a pivotal function to know the dissolution-mediated clearance and security of NDDS. Prevalent in vitro dissolution strategies for NDDS and their limitations are mentioned in this overview, amongst which USP four is gaining extra curiosity lately. Researchers are working diligently to develop biorelevant in vitro launch assays to make sure optimum therapeutic efficiency of generic variations of those NDDS. This article focuses on these research and presents vital concerns for the future improvement of clinically related in vitro launch strategies.
A overview of the proof on the danger of congenital malformations and neurodevelopmental issues in affiliation with antiseizure medicines throughout being pregnant
IntroductionThe majority of ladies with epilepsy require remedy with antiseizure medicines (ASM) all through being pregnant. However, in utero publicity to a number of ASM has been related to an elevated danger of congenital malformations and/or neurodevelopmental issues (CM/NDD) in the baby, however observational proof is methodologically heterogeneous.Areas coatedWe critically consider present proof on the danger of CM/NDD in youngsters of ladies with epilepsy after in utero publicity to totally different ASM.
We spotlight traits of various information sources and talk about their advantages and drawbacks. This overview consists of proof revealed earlier than December 2020 (non-systematic literature search).Expert opinionGiven the lack of randomized managed trials, proof on in utero security of ASM originates from methodologically heterogeneous post-marketing observational research primarily based on registries, potential cohorts, and giant digital well being databases.
Dbndd1 ORF Vector (Rat) (pORF) |
|||
| ORF065791 | ABM | 1.0 ug DNA | 607.2 EUR |
DBNDD1 ORF Vector (Human) (pORF) |
|||
| ORF018059 | ABM | 1.0 ug DNA | 486 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042642 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042643 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042644 | ABM | 1.0 ug DNA | 607.2 EUR |
Human DBNDD1 Antibody |
|||
| 33409-05111 | AssayPro | 150 ug | 313.2 EUR |
DBNDD1 protein (His tag) |
|||
| 80R-2386 | Fitzgerald | 100 ug | 386.4 EUR |
|
Description: Purified recombinant Human DBNDD1 protein (His tag) |
|||
Mouse DBNDD1 shRNA Plasmid |
|||
| 20-abx977710 | Abbexa |
|
|
Human DBNDD1 shRNA Plasmid |
|||
| 20-abx962250 | Abbexa |
|
|
Rat DBNDD1 shRNA Plasmid |
|||
| 20-abx990198 | Abbexa |
|
|
DBNDD1 Recombinant Protein (Rat) |
|||
| RP197369 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Human) |
|||
| RP054174 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127922 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127925 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127928 | ABM | 100 ug | Ask for price |
DBNDD1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV668966 | ABM | 1.0 ug DNA | 616.8 EUR |
DBNDD1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV668967 | ABM | 1.0 ug DNA | 686.4 EUR |
DBNDD1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV668968 | ABM | 1.0 ug DNA | 686.4 EUR |
DBNDD1 Protein Vector (Human) (pPB-C-His) |
|||
| PV072233 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPB-N-His) |
|||
| PV072234 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPM-C-HA) |
|||
| PV072235 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPM-C-His) |
|||
| PV072236 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170566 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170567 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170568 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170569 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170570 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170571 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170572 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170573 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170574 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170575 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170576 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170577 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPB-C-His) |
|||
| PV263162 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPB-N-His) |
|||
| PV263163 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV263164 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPM-C-His) |
|||
| PV263165 | ABM | 500 ng | 723.6 EUR |
Human DBNDD1 Antibody (Biotin Conjugate) |
|||
| 33409-05121 | AssayPro | 150 ug | 442.8 EUR |
Human DBNDD1 AssayLite Antibody (FITC Conjugate) |
|||
| 33409-05141 | AssayPro | 150 ug | 513.6 EUR |
Human DBNDD1 AssayLite Antibody (RPE Conjugate) |
|||
| 33409-05151 | AssayPro | 150 ug | 513.6 EUR |
Human DBNDD1 AssayLite Antibody (APC Conjugate) |
|||
| 33409-05161 | AssayPro | 150 ug | 513.6 EUR |
Human DBNDD1 AssayLite Antibody (PerCP Conjugate) |
|||
| 33409-05171 | AssayPro | 150 ug | 565.2 EUR |
DBNDD1 sgRNA CRISPR Lentivector set (Human) |
|||
| K0563301 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3858501 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6273401 | ABM | 3 x 1.0 ug | 406.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0563302 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0563303 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0563304 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3858502 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3858503 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3858504 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6273402 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6273403 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6273404 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 3'UTR Luciferase Stable Cell Line |
|||
| TU005580 | ABM | 1.0 ml | 1672.8 EUR |
Dbndd1 3'UTR GFP Stable Cell Line |
|||
| TU253166 | ABM | 1.0 ml | Ask for price |
Dbndd1 3'UTR Luciferase Stable Cell Line |
|||
| TU104864 | ABM | 1.0 ml | Ask for price |
DBNDD1 3'UTR GFP Stable Cell Line |
|||
| TU055580 | ABM | 1.0 ml | 1672.8 EUR |
Dbndd1 3'UTR Luciferase Stable Cell Line |
|||
| TU203166 | ABM | 1.0 ml | Ask for price |
Dbndd1 3'UTR GFP Stable Cell Line |
|||
| TU154864 | ABM | 1.0 ml | Ask for price |
Recombinant Human DBNDD1 Protein, His, E.coli-1mg |
|||
| QP11597-1mg | EnQuireBio | 1mg | 3308.4 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-20ug |
|||
| QP11597-20ug | EnQuireBio | 20ug | 241.2 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-5ug |
|||
| QP11597-5ug | EnQuireBio | 5ug | 186 EUR |
Bovine Dysbindin domain- containing protein 1, DBNDD1 ELISA KIT |
|||
| ELI-46840b | Lifescience Market | 96 Tests | 1113.6 EUR |
Human Dysbindin domain- containing protein 1, DBNDD1 ELISA KIT |
|||
| ELI-46841h | Lifescience Market | 96 Tests | 988.8 EUR |
Mouse Dysbindin domain- containing protein 1, Dbndd1 ELISA KIT |
|||
| ELI-31886m | Lifescience Market | 96 Tests | 1038 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0563305 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3858505 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6273405 | ABM | 3 x 1.0 ug | 451.2 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0563306 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0563307 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0563308 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3858506 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3858507 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3858508 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6273406 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6273407 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6273408 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 Dysbindin (Dystrobrevin Binding Protein 1) Domain Containing 1 Human Recombinant Protein |
|||
| PROTQ9H9R9 | BosterBio | Regular: 20ug | 380.4 EUR |
|
Description: DBNDD1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 182 amino acids (1-158 a.a) and having a molecular mass of 19.6kDa (Molecular weight on SDS-PAGE will appear higher).;DBNDD1 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
Cas9 Nickase Lentiviral Vector |
|||
| K005 | ABM | 10 ug | 184.8 EUR |
Cas9 Nuclease Lentiviral Vector |
|||
| K002 | ABM | 10 ug | 184.8 EUR |
dCas9-KRAB Lentiviral Vector |
|||
| K203 | ABM | 10 ug | 273.6 EUR |
pLenti-GFP Lentiviral Control Vector |
|||
| LTV-400 | Cell Biolabs | 100 µL | 741.6 EUR |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-MNDnLacZ Lentiviral Control Vector |
|||
| LTV-402 | Cell Biolabs | 10 µg | 741.6 EUR |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
Cas9 Double Mutant Lentiviral Vector |
|||
| K012 | ABM | 10 ug | 643.2 EUR |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| VPK-212 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-Neo Lentiviral Expression Vector |
|||
| VPK-213 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| VPK-214 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-GFP-Puro Lentiviral Control Vector |
|||
| LTV-401 | Cell Biolabs | 10 µg | 741.6 EUR |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pLenti-RFP-Puro Lentiviral Control Vector |
|||
| LTV-403 | Cell Biolabs | 100 µL | 741.6 EUR |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-GFP-LC3 Lentiviral Expression Vector |
|||
| LTV-801 | Cell Biolabs | 10 µg | 1444.8 EUR |
|
Description: Expression vector contains a fusion of GFP and LC3. A separate GFP control vector is also included. |
|||
ESR1 Lentiviral Vector (Human) (pLenti-II) |
|||
| LV010008 | ABM | 1.0 ug DNA | 379.2 EUR |
pSMPUW Universal Lentiviral Expression Vector (Promoterless) |
|||
| VPK-211 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest and a gene-specific promoter into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293T or 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Puro Lentiviral Expression Vector |
|||
| VPK-215 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Neo Lentiviral Expression Vector |
|||
| VPK-216 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Hygro Lentiviral Expression Vector |
|||
| VPK-217 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
pSMPUW-IRES-Blasticidin Lentiviral Expression Vector |
|||
| VPK-219 | Cell Biolabs | 10 µg | 748.8 EUR |
|
Description: Clone your gene of interest into this Lentiviral Expression Vector, then co-transfect along with lentiviral packaging vectors into a packaging cell line such as 293LTV. This expression vector is compatible with any 2nd or 3rd generation lentiviral packaging system, but due to its design it is best matched with our ViraSafe packaging vectors to produce the highest viral titer. |
|||
ERAF Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810237 | ABM | 1.0 ug DNA | 379.2 EUR |
ERAF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810241 | ABM | 1.0 ug DNA | 379.2 EUR |
ERAF Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810242 | ABM | 1.0 ug DNA | 379.2 EUR |
C6orf218 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810243 | ABM | 1.0 ug DNA | 379.2 EUR |
C6orf218 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810247 | ABM | 1.0 ug DNA | 379.2 EUR |
C6orf218 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810248 | ABM | 1.0 ug DNA | 379.2 EUR |
BXDC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810249 | ABM | 1.0 ug DNA | 379.2 EUR |
BXDC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810253 | ABM | 1.0 ug DNA | 379.2 EUR |
BXDC1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810254 | ABM | 1.0 ug DNA | 379.2 EUR |
C17orf45 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810255 | ABM | 1.0 ug DNA | 379.2 EUR |
C17orf45 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810259 | ABM | 1.0 ug DNA | 379.2 EUR |
C17orf45 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810260 | ABM | 1.0 ug DNA | 379.2 EUR |
FAM86C Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810261 | ABM | 1.0 ug DNA | 379.2 EUR |
FAM86C Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810265 | ABM | 1.0 ug DNA | 379.2 EUR |
FAM86C Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810266 | ABM | 1.0 ug DNA | 379.2 EUR |
C3orf31 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810267 | ABM | 1.0 ug DNA | 379.2 EUR |
C3orf31 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810271 | ABM | 1.0 ug DNA | 379.2 EUR |
C3orf31 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810272 | ABM | 1.0 ug DNA | 379.2 EUR |
C13orf16 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810279 | ABM | 1.0 ug DNA | 379.2 EUR |
C13orf16 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810283 | ABM | 1.0 ug DNA | 379.2 EUR |
C13orf16 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810284 | ABM | 1.0 ug DNA | 379.2 EUR |
C21ORF55 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810285 | ABM | 1.0 ug DNA | 379.2 EUR |
C21ORF55 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810289 | ABM | 1.0 ug DNA | 379.2 EUR |
C21ORF55 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810290 | ABM | 1.0 ug DNA | 379.2 EUR |
FLJ10357 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810291 | ABM | 1.0 ug DNA | 379.2 EUR |
FLJ10357 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810295 | ABM | 1.0 ug DNA | 379.2 EUR |
FLJ10357 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810296 | ABM | 1.0 ug DNA | 379.2 EUR |
C13orf3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810297 | ABM | 1.0 ug DNA | 379.2 EUR |
C13orf3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810301 | ABM | 1.0 ug DNA | 379.2 EUR |
C13orf3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810302 | ABM | 1.0 ug DNA | 379.2 EUR |
ARL17 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810303 | ABM | 1.0 ug DNA | 379.2 EUR |
ARL17 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810307 | ABM | 1.0 ug DNA | 379.2 EUR |
ARL17 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810308 | ABM | 1.0 ug DNA | 379.2 EUR |
HSPC047 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810309 | ABM | 1.0 ug DNA | 379.2 EUR |
HSPC047 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810313 | ABM | 1.0 ug DNA | 379.2 EUR |
HSPC047 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810314 | ABM | 1.0 ug DNA | 379.2 EUR |
C9orf68 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810315 | ABM | 1.0 ug DNA | 379.2 EUR |
C9orf68 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810319 | ABM | 1.0 ug DNA | 379.2 EUR |
C9orf68 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810320 | ABM | 1.0 ug DNA | 379.2 EUR |
C18orf22 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810321 | ABM | 1.0 ug DNA | 379.2 EUR |
C18orf22 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810325 | ABM | 1.0 ug DNA | 379.2 EUR |
C18orf22 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810326 | ABM | 1.0 ug DNA | 379.2 EUR |
KIAA0774 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810327 | ABM | 1.0 ug DNA | 379.2 EUR |
KIAA0774 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810331 | ABM | 1.0 ug DNA | 379.2 EUR |
KIAA0774 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810332 | ABM | 1.0 ug DNA | 379.2 EUR |
BXDC5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810333 | ABM | 1.0 ug DNA | 379.2 EUR |
BXDC5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810337 | ABM | 1.0 ug DNA | 379.2 EUR |
BXDC5 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810338 | ABM | 1.0 ug DNA | 379.2 EUR |
IL8RA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810339 | ABM | 1.0 ug DNA | 379.2 EUR |
IL8RA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810343 | ABM | 1.0 ug DNA | 379.2 EUR |
IL8RA Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810344 | ABM | 1.0 ug DNA | 379.2 EUR |
RBM9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810345 | ABM | 1.0 ug DNA | 379.2 EUR |
RBM9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810349 | ABM | 1.0 ug DNA | 379.2 EUR |
RBM9 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810350 | ABM | 1.0 ug DNA | 379.2 EUR |
FAM62B Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810351 | ABM | 1.0 ug DNA | 379.2 EUR |
FAM62B Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810355 | ABM | 1.0 ug DNA | 379.2 EUR |
FAM62B Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810356 | ABM | 1.0 ug DNA | 379.2 EUR |
BC013798 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810357 | ABM | 1.0 ug DNA | 379.2 EUR |
BC013798 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810361 | ABM | 1.0 ug DNA | 379.2 EUR |
BC013798 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810362 | ABM | 1.0 ug DNA | 379.2 EUR |
RTCD1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810363 | ABM | 1.0 ug DNA | 379.2 EUR |
RTCD1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810367 | ABM | 1.0 ug DNA | 379.2 EUR |
RTCD1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810368 | ABM | 1.0 ug DNA | 379.2 EUR |
TTC15 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810369 | ABM | 1.0 ug DNA | 379.2 EUR |
TTC15 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810373 | ABM | 1.0 ug DNA | 379.2 EUR |
TTC15 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810374 | ABM | 1.0 ug DNA | 379.2 EUR |
RAD51L1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810375 | ABM | 1.0 ug DNA | 379.2 EUR |
RAD51L1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810379 | ABM | 1.0 ug DNA | 379.2 EUR |
RAD51L1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810380 | ABM | 1.0 ug DNA | 379.2 EUR |
TSP50 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810381 | ABM | 1.0 ug DNA | 379.2 EUR |
TSP50 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810385 | ABM | 1.0 ug DNA | 379.2 EUR |
TSP50 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810386 | ABM | 1.0 ug DNA | 379.2 EUR |
TMEM22 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810387 | ABM | 1.0 ug DNA | 379.2 EUR |
TMEM22 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810391 | ABM | 1.0 ug DNA | 379.2 EUR |
TMEM22 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810392 | ABM | 1.0 ug DNA | 379.2 EUR |
KTELC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810393 | ABM | 1.0 ug DNA | 379.2 EUR |
KTELC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810397 | ABM | 1.0 ug DNA | 379.2 EUR |
KTELC1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810398 | ABM | 1.0 ug DNA | 379.2 EUR |
C9orf68 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810399 | ABM | 1.0 ug DNA | 379.2 EUR |
C9orf68 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810403 | ABM | 1.0 ug DNA | 379.2 EUR |
C9orf68 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810404 | ABM | 1.0 ug DNA | 379.2 EUR |
LASS4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810405 | ABM | 1.0 ug DNA | 379.2 EUR |
LASS4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810409 | ABM | 1.0 ug DNA | 379.2 EUR |
LASS4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810410 | ABM | 1.0 ug DNA | 379.2 EUR |
TMEM49 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810411 | ABM | 1.0 ug DNA | 379.2 EUR |
TMEM49 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810415 | ABM | 1.0 ug DNA | 379.2 EUR |
TMEM49 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810416 | ABM | 1.0 ug DNA | 379.2 EUR |
C2orf24 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV810417 | ABM | 1.0 ug DNA | 379.2 EUR |
C2orf24 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV810421 | ABM | 1.0 ug DNA | 379.2 EUR |
C2orf24 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV810422 | ABM | 1.0 ug DNA | 379.2 EUR |
Is has been clearly demonstrated that valproate is related to a excessive danger of CM/NDD, whereas lamotrigine and levetiracetam are comparatively secure. However, proof is much less express for different ASM. Reported dangers differ relying on the measurement and origin of the underlying examine inhabitants, the definition of publicity and outcomes, and different features of the examine design. Increased collaboration between information sources to extend pattern measurement are fascinating.
0